Michal Heger

Dr. Michal Heger is a Researcher at Utrecht University's Faculty of Science, specifically within the Membrane Biochemistry & Biophysics department. He also holds the position of Professor of photonanomedicine at Jiaxing University Medical College in China and serves as Editor-in-chief of the Journal of Clinical and Translational Research. Additionally, he is Chief formulation officer at Nurish.Me in San Diego.

Dr. Heger's research primarily focuses on the development of minimally invasive diagnostic and therapeutic modalities for treatment-resistant cancers, with special emphasis on bile duct cancer (extrahepatic cholangiocarcinoma, eCCA). His work follows three pillars: minimally invasive approaches, patient-friendly treatments, and affordable solutions. Photodynamic therapy (PDT) forms the core of his research program, where he investigates nanoscale carrier platforms for photosensitizer delivery, cancer cell responses to PDT, PDT-induced immune responses, and representative cell and animal models for cholangiocarcinoma.

His publication record shows significant expertise in photodynamic therapy, with numerous articles spanning from 2012 to 2025. The research trends indicate a strong focus on nanotechnology applications in cancer therapy, particularly in developing targeted delivery systems for photosensitizers and combination therapies. His work bridges basic science with clinical applications, especially in difficult-to-treat cancers where conventional approaches have limited success.

Dr. Heger collaborates extensively with various research groups, particularly in the areas of liquid biopsies and molecular profiling for cancer diagnostics and therapy monitoring. His work often involves interdisciplinary approaches combining pharmacology, nanotechnology, and molecular biology to address challenging clinical problems in oncology.